News from medivir A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 05, 2020, 02:45 ET Medivir appoints Dr. Tom Morris as interim Chief Medical Officer

Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Dr. Tom Morris as interim Chief Medical Officer effective October 5, 2020. Dr....


Aug 20, 2020, 02:50 ET Medivir AB - Interim Report January - June 2020

April - June Significant events during the quarter Following the positive opinion given by the European Medicines Agency (EMA), the European...


Aug 18, 2020, 02:53 ET Yilmaz Mahshid takes office as CEO of Medivir on 14 September

Medivir AB (Nasdaq Stockholm: MVIR) announced today that Dr. Yilmaz Mahshid will assume his position as CEO on September 14, 2020. Uli Hacksell, who...


Jul 06, 2020, 02:41 ET Medivir and SciLifeLab Enter Collaboration on Potential SARS CoV-2 Inhibitors

Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has entered a research collaboration with the Drug Discovery and Development Platform...


Jul 03, 2020, 01:39 ET The European Commission has Granted Orphan Medicinal Product Designation in the EU for MIV-818

Medivir AB (Nasdaq Stockholm: MVIR) today announced that the European Commission, in accordance with the opinion from the European Medicines Agency...


May 26, 2020, 02:40 ET Medivir Appoints Yilmaz Mahshid as New CEO

Medivir AB (Nasdaq Stockholm: MVIR) today announced that its Board of Directors has appointed Yilmaz Mahshid as the new CEO of the company. Yilmaz...


May 06, 2020, 02:47 ET FDA Grants MIV-818 Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma

Medivir AB (Nasdaq Stockholm: MVIR) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to...


May 05, 2020, 10:42 ET Resolutions at the Annual General Meeting in Medivir on 5 May 2020

Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director The annual...


May 05, 2020, 02:51 ET Medivir AB - Interim Report January - March 2020

Positive results for MIV-818 and continued tempo in business development January - March Significant events during the quarter Data from the phase Ia ...


Apr 30, 2020, 02:59 ET Medivir Receives Positive Opinion on Orphan Medicinal Drug Designation by the European Medicines Agency for MIV-818

Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has received positive opinion from the Committee for Orphan Medicinal Products on orphan...


Apr 15, 2020, 10:18 ET Medivir Announces Departure of Chief Medical Officer

Medivir AB (Nasdaq Stockholm: MVIR) announces that Linda Basse, Chief Medical Officer at Medivir will leave the company on September 30, 2020. A...


Apr 06, 2020, 08:09 ET Medivir 2019 Annual Report Published

Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2019 now is available at the company's website: www.medivir.com. The...


Apr 06, 2020, 03:34 ET Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB are hereby summoned to the annual general meeting on Tuesday 5 May 2020 at 2 p.m. at Tändstickspalatset, Västra...


Mar 16, 2020, 03:50 ET Medivir and Tango Therapeutics Sign License Agreement for Preclinical Asset

Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has entered into a license agreement with US biotech company Tango Therapeutics for one...


Mar 10, 2020, 04:18 ET First Liver Cancer Patient Dosed in the MIV-818 Phase Ib Study

Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with advanced liver cancer has been dosed in the phase Ib study of MIV-818....


Mar 02, 2020, 02:40 ET Medivir Presents Positive Data From the Completed Phase Ia Study With MIV-818 in Patients With Advanced Liver Cancer

Medivir AB (Nasdaq Stockholm: MVIR) announces that new data from the completed phase Ia study with MIV-818 will be presented at the R&D day hosted by ...


Feb 25, 2020, 02:53 ET Invitation to Medivir's R&D Day on March 2, 2020

Medivir AB (Nasdaq Stockholm: MVIR) invites investors, analysts and the media to a R&D Day in Stockholm, Monday March 2, 2020, at 14:00 to 16:30 CET. ...


Feb 24, 2020, 10:09 ET Medivir and Shijiazhuang Yuanmai Biotechnology Sign Licensing Agreement Regarding Manufacturing and Sales of Xerclear® in China

Medivir AB (Nasdaq Stockholm: MVIR) announces today that the company has signed a licensing agreement for Medivir's Xerclear® for labial herpes with...


Feb 13, 2020, 02:51 ET Medivir AB: Year End Report January-December 2019

October - December Significant events during the quarter Preclinical data showing that in addition to its direct effect on cancer cells, MIV-818 also ...


Feb 11, 2020, 02:45 ET Medivir Invites to R&D Day on March 2, 2020

Medivir AB (Nasdaq Stockholm: MVIR) invites investors, analysts and the media to an R&D Day in Stockholm, Monday March 2, 2020, at 14:00 to 16:30 CET....


Jan 30, 2020, 02:49 ET Medivir has Received Notices of Allowance in the EU and Japan for MIV-818 Patent Applications

Medivir AB (Nasdaq Stockholm: MVIR) reports that the MIV-818 patent portfolio has been reinforced by the issue of notices of allowance from the...


Jan 20, 2020, 02:57 ET Medivir's Phase II Study of MIV-711 in Patients With Osteoarthritis Published in Annals of Internal Medicine

Medivir AB (Nasdaq Stockholm: MVIR) announces that the phase II study of MIV-711 in patients with osteoarthritis has been published in the respected...


Dec 18, 2019, 02:50 ET Investigator-initiated Phase II Clinical Study of Remetinostat Started in Patients With Squamous Cell Carcinoma

Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled and is being dosed with remetinostat gel 1% in an...


Dec 16, 2019, 10:12 ET Futility Analysis Performed of the Phase II Combination Study with Birinapant and Keytruda® in Colorectal Cancer Patients

Medivir AB (Nasdaq Stockholm: MVIR) announces today that the independent safety committee (IDMC) for the phase II study of birinapant in combination...


Dec 10, 2019, 02:46 ET Medivir Receives the International Diamond Prize for Excellence in Quality

Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company has been awarded the International Diamond Prize for Excellence in Quality 2019. ...